{"id":23791,"date":"2025-09-28T06:44:57","date_gmt":"2025-09-28T06:44:57","guid":{"rendered":"https:\/\/nanamedia.org\/en\/2025\/09\/28\/an-opportunity-to-end-the-global-hiv-epidemic-inexpensive-preventive-medication-to-equip-yourself-on-2027\/"},"modified":"2025-09-28T06:44:59","modified_gmt":"2025-09-28T06:44:59","slug":"an-opportunity-to-end-the-global-hiv-epidemic-inexpensive-preventive-medication-to-equip-yourself-on-2027","status":"publish","type":"post","link":"https:\/\/nanamedia.org\/en\/2025\/09\/28\/an-opportunity-to-end-the-global-hiv-epidemic-inexpensive-preventive-medication-to-equip-yourself-on-2027\/","title":{"rendered":"An opportunity to end the global HIV epidemic: inexpensive preventive medication to equip yourself on 2027"},"content":{"rendered":"<h2>Groundbreaking HIV Prevention Medication<\/h2>\n<p>Generic versions of a groundbreaking injectable HIV prevention medication should be available in more than 100 countries by 2027 for $40 a year. <\/p>\n<h2>Availability and Affordability<\/h2>\n<p>The two organizations have closed separate agreements with Indian pharmaceutical companies to produce cheaper generic versions of Lenacapavir, a twice annual injection. <\/p>\n<h2>Efficacy of Lenacapavir<\/h2>\n<p>Lenacapavir reduces the risk of HIV transmission by more than 99.9 percent for countries with low and medium income. <\/p>\n<h2>Details of the Agreement<\/h2>\n<p>Details of the agreements were provided by Unitaid Executive Director Philippe Duneton. <\/p>\n<h2>Impact on Low and Medium Income Countries<\/h2>\n<p>The availability of generic versions of Lenacapavir is expected to have a significant impact on the prevention of HIV transmission in low and medium income countries.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Groundbreaking HIV Prevention Medication Generic versions of a groundbreaking injectable HIV prevention medication should be available in more than 100 countries by 2027 for $40 a year. Availability and Affordability The two organizations have closed separate agreements with Indian pharmaceutical companies to produce cheaper generic versions of Lenacapavir, a twice annual injection. Efficacy of Lenacapavir<\/p>\n","protected":false},"author":1,"featured_media":23792,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40],"tags":[11059,11556,294,1035,2429],"class_list":{"0":"post-23791","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-generic-drug","9":"tag-lenacapavir","10":"tag-pandemic","11":"tag-pharmaceutical-industry","12":"tag-preventive-healthcare"},"_links":{"self":[{"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/posts\/23791","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/comments?post=23791"}],"version-history":[{"count":1,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/posts\/23791\/revisions"}],"predecessor-version":[{"id":23793,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/posts\/23791\/revisions\/23793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/media\/23792"}],"wp:attachment":[{"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/media?parent=23791"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/categories?post=23791"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanamedia.org\/en\/wp-json\/wp\/v2\/tags?post=23791"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}